VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Primary B-NHL, PTCL (ALK+ anaplastic large cell    │ Primary B-NHL, PTCL (ALK+ anaplastic large cell    │     100 │
│ lymphoma and NK(natural killer cell )/T cell       │ lymphoma and NK(natural killer cell )/T cell       │         │
│ lymphoma were excluded) or HL patients confirmed   │ lymphoma were excluded) or HL patients confirmed   │         │
│ by histopathology                                  │ by histopathology                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ At least one measurable lesion                     │ At least one measurable lesion                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Renal function: serum creatinine is 44-133 mmol/L  │ Renal function: serum creatinine is 44-133 mmol/L  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ New York Heart Association (NYHA) heart function   │ New York Heart Association (NYHA) heart function   │     100 │
│ classification is I-II grade                       │ classification is I-II grade                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ signed informed consent                            │ signed informed consent                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with severe complications or severe       │ Patients with severe complications or severe       │     100 │
│ infection                                          │ infection                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Invasion of central nervous system                 │ Invasion of central nervous system                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with severe heart disease history,        │ Patients with severe heart disease history,        │     100 │
│ including ventricular tachycardia (VT), atrial     │ including ventricular tachycardia (VT), atrial     │         │
│ fibrillation (AF), heart block, myocardial         │ fibrillation (AF), heart block, myocardial         │         │
│ infarction (MI), congestive heart failure (CHF),   │ infarction (MI), congestive heart failure (CHF),   │         │
│ coronary heart disease patients needed therapy     │ coronary heart disease patients needed therapy     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ patients with severe allergic constitution, or     │ patients with severe allergic constitution, or     │     100 │
│ those who are allergic to or intolerant of drug    │ those who are allergic to or intolerant of drug    │         │
│ composition in chemotherapy regimens; with other   │ composition in chemotherapy regimens; with other   │         │
│ malignant tumors in the past 5 years               │ malignant tumors in the past 5 years               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ patients received doxorubicin therapy, total       │ patients received doxorubicin therapy, total       │     100 │
│ cumulative dose of adriamycin was more than 300    │ cumulative dose of adriamycin was more than 300    │         │
│ mg/m2, total cumulative dose of epirubicin was     │ mg/m2, total cumulative dose of epirubicin was     │         │
│ more than 450 mg/m2                                │ more than 450 mg/m2                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients participate in other clinical studies     │ Patients participate in other clinical studies     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other patients who are not suitable for the study  │ Other patients who are not suitable for the study  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Routine blood test：WBC≥3.0×109/L，Neutrophils≥1.5 │ Routine blood test:WBC=3.0×109/L,Neutrophils=1.5×1 │      89 │
│ ×109/L，Hb≥100g/L，Platelet≥80×109/L； LVEF≥50%    │ 09/L,Hb=100g/L,Platelet=80×109/L; LVEF=50%         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ages ≥18 years old, \< 80 years old                │ Ages =18 years old, < 80 years old                 │      96 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Expected survival time≥3 months                    │ Expected survival time=3 months                    │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Liver function: transaminase≤2.5× upper limit of   │ Liver function: transaminase=2.5× upper limit of   │      97 │
│ normal value，bilirubin≤1.5×upper limit of normal  │ normal value,bilirubin=1.5×upper limit of normal   │         │
│ value                                              │ value                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ECOG (Eastern Cooperative Oncology Group）score:   │ ECOG (Eastern Cooperative Oncology Group)score:    │      98 │
│ 0-2                                                │ 0-2                                                │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                      │   Score │
╞═══════════════════════════════════╪════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Ages =18 years old, < 80 years old │      39 │
├───────────────────────────────────┼────────────────────────────────────┼─────────┤
│ Must have maximum age of 80 Years │ Ages =18 years old, < 80 years old │      42 │
╘═══════════════════════════════════╧════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 97
Average Levenshtein Ratio of individual lines: 92.52631578947368
OverAll Ratio: 94.76315789473685
